CA2922684A1 - Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases - Google Patents
Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases Download PDFInfo
- Publication number
- CA2922684A1 CA2922684A1 CA2922684A CA2922684A CA2922684A1 CA 2922684 A1 CA2922684 A1 CA 2922684A1 CA 2922684 A CA2922684 A CA 2922684A CA 2922684 A CA2922684 A CA 2922684A CA 2922684 A1 CA2922684 A1 CA 2922684A1
- Authority
- CA
- Canada
- Prior art keywords
- inhibitor
- cancer
- alk
- combination according
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 title claims abstract description 6
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 title claims abstract description 6
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 title claims abstract description 5
- 201000010099 disease Diseases 0.000 title claims abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract 7
- 230000002062 proliferating effect Effects 0.000 title claims abstract 7
- 239000003795 chemical substances by application Substances 0.000 claims abstract 7
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 101150023956 ALK gene Proteins 0.000 claims 3
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims 3
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical group O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 claims 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 2
- 108091007914 CDKs Proteins 0.000 claims 2
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 2
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 claims 2
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims 2
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims 2
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims 2
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 241000237519 Bivalvia Species 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 235000020639 clam Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940125436 dual inhibitor Drugs 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 208000014500 neuronal tumor Diseases 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 208000013076 thyroid tumor Diseases 0.000 claims 1
- 208000025421 tumor of uterus Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361871275P | 2013-08-28 | 2013-08-28 | |
| US61/871,275 | 2013-08-28 | ||
| PCT/US2014/053244 WO2015031666A1 (en) | 2013-08-28 | 2014-08-28 | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2922684A1 true CA2922684A1 (en) | 2015-03-05 |
Family
ID=51541330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2922684A Abandoned CA2922684A1 (en) | 2013-08-28 | 2014-08-28 | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20160361314A1 (enExample) |
| EP (1) | EP3038652B1 (enExample) |
| JP (1) | JP6479812B2 (enExample) |
| KR (1) | KR20160047521A (enExample) |
| CN (1) | CN106029099A (enExample) |
| AU (3) | AU2014312261A1 (enExample) |
| BR (1) | BR112016004358A8 (enExample) |
| CA (1) | CA2922684A1 (enExample) |
| ES (1) | ES2674361T3 (enExample) |
| MX (1) | MX2016002580A (enExample) |
| RU (1) | RU2016110874A (enExample) |
| WO (1) | WO2015031666A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016167511A2 (ko) * | 2015-04-14 | 2016-10-20 | 한국화학연구원 | N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| KR101772134B1 (ko) | 2015-04-14 | 2017-08-29 | 한국화학연구원 | N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| US11208630B2 (en) * | 2015-12-24 | 2021-12-28 | University Of Florida Research Foundation, Incorporated | AAV production using suspension adapted cells |
| US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| CN111837146B (zh) | 2018-01-08 | 2024-10-15 | G1治疗公司 | G1t38优异剂量方案 |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| WO2020206137A1 (en) * | 2019-04-04 | 2020-10-08 | Dana-Farber Cancer Institute, Inc. | Cdk2/5 degraders and uses thereof |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| EP4062938A4 (en) | 2019-11-18 | 2023-11-29 | Chugai Seiyaku Kabushiki Kaisha | COMBINATION MEDICINAL PRODUCTS |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TW202146017A (zh) * | 2020-03-05 | 2021-12-16 | 美商輝瑞股份有限公司 | 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合 |
| CN116261455B (zh) * | 2020-09-25 | 2024-11-01 | 苏州亚盛药业有限公司 | 一种药物组合物及其在治疗癌症中的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ590601A (en) * | 2006-12-08 | 2011-09-30 | Irm Llc | Pyrimidine compounds especially 4-phenylamino-2-arylamino-pyrimidine derivatives and compositions as protein kinase inhibitors |
| PT2091918E (pt) * | 2006-12-08 | 2014-11-24 | Irm Llc | Compostos e composições como inibidores de proteína cinase |
| KR20130140222A (ko) * | 2008-08-22 | 2013-12-23 | 노파르티스 아게 | Ｃｄｋ 억제제로서 피롤로피리미딘 화합물 |
| AU2010248886A1 (en) * | 2009-05-13 | 2011-12-01 | The University Of North Carolina At Chapel Hill | Cyclin dependent kinase inhibitors and methods of use |
| CA2800327A1 (en) * | 2010-04-13 | 2011-10-20 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer |
| CA2824092C (en) * | 2011-02-02 | 2020-06-30 | Irm Llc | Use of alk inhibitors for the treatment of eml4-alk+ non-small cell lung cancer |
-
2014
- 2014-08-28 CA CA2922684A patent/CA2922684A1/en not_active Abandoned
- 2014-08-28 MX MX2016002580A patent/MX2016002580A/es unknown
- 2014-08-28 ES ES14766301.7T patent/ES2674361T3/es active Active
- 2014-08-28 RU RU2016110874A patent/RU2016110874A/ru not_active Application Discontinuation
- 2014-08-28 WO PCT/US2014/053244 patent/WO2015031666A1/en not_active Ceased
- 2014-08-28 JP JP2016537859A patent/JP6479812B2/ja not_active Expired - Fee Related
- 2014-08-28 EP EP14766301.7A patent/EP3038652B1/en active Active
- 2014-08-28 CN CN201480059490.0A patent/CN106029099A/zh active Pending
- 2014-08-28 US US14/913,828 patent/US20160361314A1/en not_active Abandoned
- 2014-08-28 BR BR112016004358A patent/BR112016004358A8/pt not_active IP Right Cessation
- 2014-08-28 KR KR1020167007656A patent/KR20160047521A/ko not_active Withdrawn
- 2014-08-28 AU AU2014312261A patent/AU2014312261A1/en not_active Abandoned
-
2017
- 2017-08-25 AU AU2017219093A patent/AU2017219093A1/en not_active Abandoned
-
2018
- 2018-07-16 US US16/035,774 patent/US20180318305A1/en not_active Abandoned
- 2018-09-27 AU AU2018236813A patent/AU2018236813A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017219093A1 (en) | 2017-09-14 |
| JP6479812B2 (ja) | 2019-03-06 |
| KR20160047521A (ko) | 2016-05-02 |
| US20160361314A1 (en) | 2016-12-15 |
| BR112016004358A8 (pt) | 2020-02-11 |
| RU2016110874A3 (enExample) | 2018-06-27 |
| US20180318305A1 (en) | 2018-11-08 |
| JP2016529285A (ja) | 2016-09-23 |
| EP3038652A1 (en) | 2016-07-06 |
| AU2018236813A1 (en) | 2018-10-18 |
| RU2016110874A (ru) | 2017-10-04 |
| ES2674361T3 (es) | 2018-06-29 |
| EP3038652B1 (en) | 2018-03-21 |
| CN106029099A (zh) | 2016-10-12 |
| MX2016002580A (es) | 2016-10-26 |
| WO2015031666A1 (en) | 2015-03-05 |
| AU2014312261A1 (en) | 2016-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2922684A1 (en) | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases | |
| Sica et al. | Oxidative phosphorylation as a potential therapeutic target for cancer therapy | |
| Nagel et al. | Drugging the addict: non‐oncogene addiction as a target for cancer therapy | |
| Li et al. | Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer | |
| Schwartz et al. | Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors | |
| Tolcher et al. | A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours | |
| JP2016501221A5 (enExample) | ||
| JP2016533366A5 (enExample) | ||
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| GB201205669D0 (en) | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof | |
| MD4643B1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
| EA201000090A1 (ru) | Тризамещенные производные пиримидина для лечения пролиферативных заболеваний | |
| EA201000092A1 (ru) | Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний | |
| BR112012026289A2 (pt) | composto orgânico para uso no tratamento de câncer do fígado | |
| EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
| JP2015520753A5 (enExample) | ||
| RU2015125307A (ru) | Комбинированная терапия | |
| JP2016529285A5 (enExample) | ||
| WO2008116053A3 (en) | Fap-activated chemotherapeutic compounds, and methods of use thereof | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| JP2017514806A5 (enExample) | ||
| MX2017000610A (es) | Metodos combinados para tratar canceres. | |
| JP2015509540A5 (enExample) | ||
| Huang et al. | Inhibition of Hec1 as a novel approach for treatment of primary liver cancer | |
| Renouf et al. | A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20200831 |